Difference between revisions of "Editing test page"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - ".4 Gy" to "40 cGy") |
Warner-admin (talk | contribs) m (Text replacement - ".7 Gy" to "70 cGy") |
||
| Line 71: | Line 71: | ||
====External beam radiotherapy==== | ====External beam radiotherapy==== | ||
*Concurrent [[External_beam_radiotherapy|radiation therapy]] by the following study-specific criteria: | *Concurrent [[External_beam_radiotherapy|radiation therapy]] by the following study-specific criteria: | ||
| − | **GOG 120, stage IIB: | + | **GOG 120, stage IIB: 170 cGy x 24 fractions, for an initial dose of 4080 cGy |
**GOG 219: 180 cGy x 23 to 25 fractions, for an initial dose of 41.4 to 45 Gy | **GOG 219: 180 cGy x 23 to 25 fractions, for an initial dose of 41.4 to 45 Gy | ||
**Pearcey et al. 2002 & Zuliani et al. 2014: 180 cGy x 25 fractions, for an initial dose of 45 Gy | **Pearcey et al. 2002 & Zuliani et al. 2014: 180 cGy x 25 fractions, for an initial dose of 45 Gy | ||
**B9E-MC-JHQS & Sehouli et al. 2012: 180 cGy x 28 fractions, for an initial dose of 5040 cGy | **B9E-MC-JHQS & Sehouli et al. 2012: 180 cGy x 28 fractions, for an initial dose of 5040 cGy | ||
| − | **GOG 120, stage III or IVA: | + | **GOG 120, stage III or IVA: 170 cGy x 30 fractions, for an initial dose of 5100 cGy |
**Yang et al. 2022: 180 cGy/fraction/day, 5 days/week, a total of 25-28 fractions | **Yang et al. 2022: 180 cGy/fraction/day, 5 days/week, a total of 25-28 fractions | ||
| Line 85: | Line 85: | ||
|- | |- | ||
|GOG 120, stage IIB | |GOG 120, stage IIB | ||
| − | | | + | |170 cGy |
|24 | |24 | ||
|4080 cGy | |4080 cGy | ||
| Line 105: | Line 105: | ||
|- | |- | ||
|GOG 120, stage III or IVA | |GOG 120, stage III or IVA | ||
| − | | | + | |170 cGy |
|30 | |30 | ||
|5100 cGy | |5100 cGy | ||
Revision as of 00:47, 1 March 2024
Radiation therapy
Radiation therapy
Links
Blah below here
Regimen variant #3, weekly cisplatin x 6, no cap
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Pearcey et al. 2002 | 1991-1996 | Phase 3 (E-esc) | RT | Did not meet primary endpoint of OS36 |
| Rose et al. 1999 (GOG 120) | 1992-1997 | Phase 3 (E-esc) | 1. Cisplatin, Fluorouracil, Hydroxyurea, RT | Did not meet co-primary endpoints of PFS/OS |
| 2. Hydroxyurea & RT | Superior OS (co-primary endpoint) | |||
| Dueñas-González et al. 2011 (B9E-MC-JHQS) | 2002-2004 | Phase 3 (C) | Cisplatin, Gemcitabine, RT | Seems to have inferior OS |
| Sehouli et al. 2012 | 2003-2008 | Phase 3 (C) | Carboplatin & Paclitaxel, then RT | Did not meet primary endpoint of PFS |
| Zuliani et al. 2014 | 2003-2010 | Phase 3 (E-esc) | RT | Superior OS1 (co-primary endpoint) (HR 0.53, 95% CI 0.31-0.92) |
| DiSilvestro et al. 2014 (GOG 219) | 2006-2009 | Phase 3 (C) | Cisplatin, Tirapazamine, RT | Did not meet primary endpoint of PFS |
| Yang et al. 2022 | 2018-2020 | Phase 3 (C) | Nedaplatin & RT | Inferior PFS |
1Reported efficacy is based on the 2020 update.
Note: In GOG 120, this regimen was intended for disease.
Chemotherapy
- Cisplatin (Platinol) 40 mg/m2 IV over 60 minutes once per day on days 1, 8, 15, 22, 29, 36, given 1 to 4 hours prior to radiation
External beam radiotherapy
- Concurrent radiation therapy by the following study-specific criteria:
- GOG 120, stage IIB: 170 cGy x 24 fractions, for an initial dose of 4080 cGy
- GOG 219: 180 cGy x 23 to 25 fractions, for an initial dose of 41.4 to 45 Gy
- Pearcey et al. 2002 & Zuliani et al. 2014: 180 cGy x 25 fractions, for an initial dose of 45 Gy
- B9E-MC-JHQS & Sehouli et al. 2012: 180 cGy x 28 fractions, for an initial dose of 5040 cGy
- GOG 120, stage III or IVA: 170 cGy x 30 fractions, for an initial dose of 5100 cGy
- Yang et al. 2022: 180 cGy/fraction/day, 5 days/week, a total of 25-28 fractions
| Study | Dose per fraction | Number of fractions | Total dose |
|---|---|---|---|
| GOG 120, stage IIB | 170 cGy | 24 | 4080 cGy |
| GOG 219 | 180 cGy | 23 to 25 | 41.4 to 45 Gy |
| Pearcey et al. 2002 & Zuliani et al. 2014 | 180 cGy | 25 fractions | 45 Gy |
| B9E-MC-JHQS & Sehouli et al. 2012 | 180 cGy | 28 fractions | 5040 cGy |
| GOG 120, stage III or IVA | 170 cGy | 30 | 5100 cGy |
| Yang et al. 2022 | 180 cGy | 25-28 | 45 to 5040 cGy |
6-week course, followed in 1 to 3 weeks by:
Subsequent treatment
- Sequential brachytherapy